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SUMMARY
Despite US sanitation advancements, millions of waterborne disease cases occur annually, 
although the precise burden of disease is not well quantified. Estimating the direct healthcare cost 
of specific infections would be useful in prioritizing waterborne disease prevention activities. 
Hospitalization and outpatient visit costs per case and total US hospitalization costs for ten 
waterborne diseases were calculated using large healthcare claims and hospital discharge 
databases. The five primarily waterborne diseases in this analysis (giardiasis, cryptosporidiosis, 
Legionnaires’ disease, otitis externa, and non-tuberculous mycobacterial infection) were 
responsible for over 40 000 hospitalizations at a cost of $970 million per year, including at least 
$430 million in hospitalization costs for Medicaid and Medicare patients. An additional 50 000 
hospitalizations for campylobacteriosis, salmonellosis, shigellosis, haemolytic uraemic syndrome, 
and toxoplasmosis cost $860 million annually ($390 million in payments for Medicaid and 
Medicare patients), a portion of which can be assumed to be due to waterborne transmission.
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INTRODUCTION
The use of filtration and disinfection to make clean water widely available has been 
recognized as one of the greatest US public health achievements of the 20th century [1, 2], 
and is credited with an estimated 50% of the reduction in mortality in major cities and nearly 
two-thirds of the decrease in child mortality observed in the early 1900s [3]. Although 
classic drinking water-associated diseases such as cholera and typhoid fever have become 
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rare, water usage in the USA has become more complex; waterborne disease is now 
associated with recreational, industrial, healthcare, agricultural, and medical uses. As a 
result, although transmission patterns have changed, waterborne illness remains a public 
health problem in the USA.
The magnitude of waterborne disease in the USA is thought to be substantial but is not well 
quantified. Almost 1400 outbreaks have been reported to the Centers for Disease Control 
and Prevention (CDC) since the current surveillance system was created in 1971 [4, 5]. 
Estimates of gastrointestinal illness caused by drinking water from public water systems fall 
between 4 and 33 million annual US cases [6, 7], but no overall estimate of the total burden 
from all water pathways exists. A more complete accounting would include illness from 
recreational water exposures, industrial exposure, and the built environment. Aerosolized 
mists generated in hospital and other building cooling and water distribution systems can 
contain pathogens such as Legionella [8] and nontuberculous mycobacteria (NTM) [9, 10]. 
Thus, Legionnaires’ disease and NTM infections are serious illnesses primarily transmitted 
by water although the transmission pathway differs from that of gastrointestinal infections 
spread through drinking water. The burden of illness due to swimming and other 
recreational water exposure also appears extensive. Swimmers at southern California 
beaches were estimated to have experienced 689 000–4 003 000 gastrointestinal illness 
episodes and 693 000 respiratory illness episodes associated with contaminated water 
annually [11], while the chlorine-tolerant parasite Cryptosporidium is estimated to cause 740 
000 cases of diarrhoeal illness each year [12].
A more precise quantification of the costs of US waterborne disease would be useful in 
prioritizing waterborne disease prevention activities and allocating limited resources, and is 
a key building block for determining the overall burden of waterborne disease in the USA. 
To begin to quantify the costs of waterborne diseases, the hospitalization costs of specific 
waterborne infections were estimated. This study summarizes data from three large health 
insurance claims databases to estimate the inpatient and outpatient cost per episode of 
selected waterborne diseases in the privately insured, Medicare-, and Medicaid-eligible 
populations and gives a national estimate of the total hospitalization costs. In a landscape of 
diminishing public health resources, these estimates are necessary components of any plan 
developed by policy-makers working to prioritize waterborne disease prevention efforts.
METHODS
Data sources for cost estimates
This analysis used data from the Marketscan® 2006 and 2007 Commercial Claims, Medicare 
Supplemental, and 2004 and 2005 Multi-State Medicaid databases from Thomson Reuters, 
the two most recent years of each database that were available at CDC. The commercial and 
Medicare databases contain anonymized medical and pharmaceutical insurance claim 
information for over 20 million employees, dependants, and retirees enrolled in primary or 
Medicare Supplemental insurance coverage through employers across the USA. The 
Medicaid database contains anonymized medical and prescription drug claims for seven 
million people enrolled in Medicaid programmes in eight states.
COLLIER et al. Page 2














All inpatients and outpatients in the databases whose record included an eligible diagnosis 
for five infections or syndromes considered to be primarily (over 50%) transmitted by water 
were included: International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes 007.1 for giardiasis, 007.4 for cryptosporidiosis, 482.84 for 
Legionnaires’ disease, 380.10, 380.12, and 380.14 for acute or malignant otitis externa, and 
031.0–031.9 for non-tuberculous pulmonary mycobacterial infection. NTM infections were 
further subdivided into pulmonary (031.0) and disseminated (031.2) infections. 
Hospitalizations and outpatient visits with ICD-9-CM code 031.0 were classified as 
pulmonary NTM infections and hospitalizations and visits with code 031.2 were classified 
as disseminated NTM infections. Because chronic otitis externa (particularly chronic otitis 
externa associated with suppurative otitis media) may be less likely to be waterborne, only 
acute (380.10 and 380.12) and malignant (380.14) otitis externa codes were included. 
Furthermore, for otitis externa hospitalizations, only cases with a primary diagnosis of otitis 
externa and no concurrent diagnosis of otitis media were included. For otitis externa 
outpatient visits, visits with a first or second diagnosis of otitis externa and no concurrent 
diagnosis of otitis media were included. Five infections or syndromes considered to be 
partially (<50%) transmitted by water were also included: ICD-9-CM codes 008.43 for 
campylobacteriosis, 003 for salmonellosis, 004 for shigellosis, 283.11 for haemolytic 
uraemic syndrome (HUS), and 130 for toxoplasmosis. Outpatient visits associated with an 
inpatient admission within 7 days were excluded from the outpatient set and included with 
inpatient costs.
Cost-per-case estimates
Using the Marketscan databases, the cost paid by the insurer, the out-of-pocket cost, and the 
sum of total payments from any source for each hospital or outpatient visit was calculated. 
Cost estimates included payments for prescription medication. The insurer cost for 
Medicare, Medicaid, and privately insured patients is the total amount paid by the insurer to 
the healthcare provider and excludes out-of-pocket payments (deductibles, co-payments, or 
co-insurance). The sum of total payments from any source is the sum of insurer payments 
and out-of-pocket payments. Because all enrollees in the Marketscan Medicare 
Supplemental database have a Medicare Supplemental insurance plan through their 
employer, payments from three sources (Medicare, the employer-provided supplemental 
plan, and out-of-pocket payments) are reported. To avoid calculating cost estimates based on 
a very small sample, cost estimates were not calculated for any disease with less than five 
patients from any payment source. Any hospitalized patient with a diagnosis code included 
in the list of immunocompromising conditions in the Prevention Quality Indicators 
Technical Specifications published by the Agency for Health Research and Quality was 
considered to be immunocompromised [13]. Because only two diagnosis codes were 
reported for outpatients, immune status was not determined. All costs were adjusted to 2007 
US dollars using the Medical Care Consumer Price Index (Bureau of Labor Statistics, US 
Department of Labor).
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National hospitalization cost estimates
To begin to quantify total waterborne disease costs, an estimate of the annual national cost 
of hospitalization for each disease was calculated. Because no single national surveillance 
system for the diseases included in this analysis exists, multiple sources were used to 
estimate the total cost of hospitalizations per year for each disease. The total number of 
hospitalizations per year for each disease was obtained from published estimates. For 
giardiasis, cryptosporidiosis, campylobacteriosis, salmonellosis, shigellosis, and 
toxoplasmosis, the estimates of Scallan et al. were used [12]. For Legionnaires’ disease, the 
midpoint (13 000 hospitalizations per year) of the range (8000–18 000) estimated by 
Marston et al. was used [14]. For otitis externa, NTM infections, and HUS, the 2006 and 
2007 Healthcare Utilization Project Nationwide Inpatient Sample (NIS) was used. The NIS 
was also used to estimate the distribution of payers (commercial, Medicare, Medicaid, 
uninsured, other) for each diagnosis. The NIS is the largest all-payer database of US hospital 
inpatient stays. To obtain the average cost per case for all payers, the cost per case for each 
payer was multiplied by the corresponding proportion of payers in the NIS. The 
commercially insured cost per case was used for uninsured cases and cases with others types 
of insurance (e.g. Tricare, the military health plan).
RESULTS
This analysis included 3684 hospitalizations and 341 157 outpatient visits. Among primarily 
waterborne diseases, cryptosporidiosis (24%) and NTM infections (21%) had the highest 
proportion of immunocompromised patients; hospitalized patients with NTM infections 
(10·5 days) and Legionnaire’s disease (10·2 days) had the longest average length of stay. 
The average length of hospitalization for giardiasis and otitis externa was 3 days; length of 
stay for cryptosporidiosis was more than twice as long (6·5 days).
Among diseases partially transmitted by water, HUS (24%) and toxoplasmosis (44%) had 
the highest proportion of immunocompromised patients. Average length of hospitalization 
for the diarrhoeal diseases campylobacteriosis, salmonellosis, and shigellosis was 4 days, 
while the average length of stay was greater for toxoplasmosis and HUS, infections with 
systemic effects (10 and 13 days, respectively).
Both hospitalization and outpatient costs per case varied by disease and by payer (Table 1). 
The majority of outpatient visits were for otitis externa (334 201 visits, average cost per visit 
$192). The most expensive primarily waterborne disease per outpatient visit was pulmonary 
NTM infection ($1649 per visit, commercially insured patients); the most expensive 
partially waterborne disease was HUS ($2591).
Over 40 000 hospitalizations for primarily waterborne diseases were estimated to occur 
annually (Table 2). Legionnaires’ disease ($33 366) and NTMs ($25 985) had the highest 
cost per episode of primarily waterborne diseases. The cost of hospitalization for 
cryptosporidiosis was nearly twice the cost of giardiasis or otitis externa. Nationally, 
insurers paid an estimated $434 million in hospitalization claims annually for Legionnaires’ 
disease alone. Over $250 million in annual hospitalization costs for Medicare patients were 
due to Legionnaires’ disease and pulmonary NTM infection, two diseases that 
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disproportionately affect the elderly. Among partially waterborne diseases, hospitalization 
for HUS ($51 261) and toxoplasmosis ($44 705) were the most costly. Average 
hospitalization costs for campylobacteriosis ($8915), salmonellosis ($7687), and shigellosis 
($8721) were lower.
Over 40 000 hospitalizations for Legionnaires’ disease, otitis externa, and NTM infection, 
diseases entirely or primarily transmitted by water, were estimated to occur each year and 
cost $970 million annually, including at least $430 million in costs for Medicare and 
Medicaid patients (because of small numbers of patients in the database, costs for Medicaid 
patients with Legionnaires’ disease could not be calculated). An additional 50 000 
hospitalizations for campylobacteriosis, salmonellosis, shigellosis, HUS, and toxoplasmosis 
cost $860 million annually ($390 million in payments for Medicaid and Medicare patients), 
an unknown portion of which can be assumed to be due to waterborne transmission.
DISCUSSION
Waterborne disease in the USA involves a complex mixture of pathogens, transmission 
routes, and water uses. The five primarily waterborne diseases in this analysis were 
responsible for over 40 000 hospitalizations at a cost of $970 million per year, and included 
at least $430 million in hospitalization costs for Medicaid and Medicare patients. These 
costs probably represent only a fraction of the overall cost of US waterborne disease and 
underscore the need for further investment in waterborne disease monitoring, economic 
analyses, and burden estimates.
Average costs for outpatient visits were also reported in this analysis. Although annual 
national costs for outpatient visits were desired, no nationally representative outpatient visit 
data source evaluated contained the pathogen-specific diagnosis codes used in this analysis, 
perhaps because the diagnoses reflect laboratory testing completed after the visit records are 
submitted to the outpatient databases. An exception is otitis externa, which is frequently 
readily apparent without diagnostic testing.
In the USA, there were 2·4 million ambulatory care visits for otitis externa in 2007 [15], and 
a UK report estimated the prevalence of otitis externa in general practice patients to be more 
than 1·2% in a 12-month period [16]. The average cost per otitis externa visit in this analysis 
was $192, implying that outpatient visits might add an additional $0·5 billion to the cost of 
this preventable waterborne disease.
A complete estimate of the true cost of waterborne illness would also include the cost of 
mortality and disability, work and time loss, and chronic sequelae, which could be 
substantial. As an example, salmonellosis was estimated to cost $2·5 billion per year in 2007 
US dollars when productivity loss and mortality (but not chronic sequelae, childcare or 
travel expenses) were accounted for [17].
The near-universal exposure to drinking water can lead to extraordinary costs in a 
community-wide outbreak. The massive 1993 outbreak of cryptosporidiosis in Milwaukee 
sickened 400 000 and was estimated to cost $96·2 million in medical costs and lost 
productivity [18]. For illness associated with recreational water, the popularity of swimming 
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implies a large population of exposed people and a high potential economic cost of illness or 
beach closure. Dwight et al. estimated that nearly 75 000 excess cases of illness were due to 
water pollution at just two beaches in Orange County, California [19], while an economic 
analysis of closures at a single Lake Michigan beach found a net economic loss of $1274–37 
030 per day (depending on the method used to assign values for health and recreation costs) 
[20].
Previous publications have estimated healthcare costs for some of the diseases included in 
this analysis. A study by Ballarino and co-workers [21] of 27 hospitalized pulmonary NTM 
patients reported a median cost of $19 876 (range $398–70 917), slightly lower than the 
mean cost of $25 409 for the 366 episodes observed this analysis. In an analysis by the 
Economic Research Service of the US Department of Agriculture, salmonellosis was 
estimated to cost $512 per outpatient visit and $10 412 per hospitalization (2007 US 
dollars), similar to the $418 (outpatient visit) and $7687 (hospitalization) observed in this 
analysis [17, 22]. A study that addressed salmonellosis in California between 1990 and 1999 
estimated an average cost of $9054 per hospitalized case, similar to the $7687 observed in 
this analysis [23].
A limitation of these estimates is their reliance on ICD-9 codes from billing records. 
Because a conservative estimate was desired, no adjustments for under-diagnosis were 
made. In particular, the estimates of hospitalization derived from the NIS instead of 
literature estimates (NTMs, HUS and otitis externa) are almost certainly lower than the 
actual number of hospitalizations because patients could have been hospitalized and treated 
for their symptoms without receiving a pathogen-specific diagnosis. The otitis externa total 
might also be lower since only hospitalized patients with a primary diagnosis of otitis 
externa and no concurrent diagnosis of otitis media were included.
A second limitation of this analysis in estimating the true cost of waterborne disease is the 
unknown proportion of disease transmission that is waterborne. Legionnaires’ disease [24], 
NTM infection [25], and otitis externa [26–28] are believed to be almost entirely transmitted 
by water, while water is thought to be the primary vehicle for transmission of giardiasis [29] 
and cryptosporidiosis [30, 31]. Campylobacteriosis, salmonellosis, shigellosis, HUS, and 
toxoplasmosis are transmitted via multiple routes (foodborne, waterborne, person-to-person, 
and zoonotic transmission have all been documented) with non-water-related routes thought 
to be the primary mode of transmission. The fraction of cases acquired through water has 
not been precisely quantified, although some attempts at describing transmission sources 
have been made [12, 32–39]. Denno et al. [33] reported that recreational water exposure was 
responsible for 44% of E. coli O157 infections (the primary infectious agent of HUS) and 
23% of campylobacteriosis cases in children, while 17% of salmonellosis cases were 
associated with septic tank use and 11% with well water use, but risk factors could differ for 
adult cases. Scallan et al. [12] estimated the foodborne percentage for campylobacteriosis 
(80%), salmonellosis (94%), shigellosis (31%), Shiga-toxin producing E. coli O157 (68%), 
and toxoplasmosis (50%). The proportions of these diseases that are transmitted via person-
to-person, zoonotic or other routes have also not been fully quantified, further obscuring the 
overall attribution picture.
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Future studies are needed to more fully describe the burden of waterborne disease in the 
USA beyond the costs of hospitalizations. The national hospitalization cost estimates 
reported here represent nearly a billion dollars or more in healthcare costs for preventable 
waterborne diseases. However, these are underestimates since they do not include the 
substantial cost of outpatient care, work and time losses, and mortality associated with 
waterborne infections (e.g. Legionella, NTM infections). With millions of waterborne 
infections estimated to occur each year, the large healthcare expenditures for 
hospitalizations reported here underscore the likelihood of a large and hidden toll of 
waterborne disease and demonstrate a need for investment in future waterborne disease 
surveillance and prevention programmes.
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Table 1























 Medicaid hospitalized cases 38 (7·9) 4·4 (1–10) $3863 n.a. $0 $3863
 Medicare Supplemental hospitalized cases 15 (6·7) 4·2 (2–9) $9773 $1283 $786 $11 842
 Commercial hospitalized cases 101 (0·0) 3·9 (1–32) $9803 n.a. $785 $10 588
Outpatients d
 Medicaid outpatient cases 307 n.a. $121 n.a. $0 $121
 Medicare Supplemental outpatient cases 45 n.a. $88 $132 $53 $273
 Commercial outpatient cases 732 n.a. $188 n.a. $65 $253
Cryptosporidiosis
Inpatients
 Medicaid hospitalized cases 18 (50·0) 7·4 (1–25) $16 203 n.a. $0 $16 203
 Medicare Supplemental hospitalized cases 8 (12·5) 5·8 (1–11) $7217 $1954 $190 $9361
 Commercial hospitalized cases 118 (21·2) 5·7 (1–70) $19 266 n.a. $807 $20 073
Outpatients d
 Medicaid outpatient cases 18 n.a. $267 n.a. $0 $267
 Medicare Supplemental outpatient cases 16 n.a. $432 $270 $55 $757
 Commercial outpatient cases 96 n.a. $457 n.a. $134 $591
Legionnaires’ disease
Inpatients
 Medicaid hospitalized cases 3 — e — e — e — e — e
 Medicare Supplemental hospitalized cases 84 (2·4) 10·3 (1–75) $22 680 $3807 $254 $26 741
 Commercial hospitalized cases 187 (10·2) 10·2 (1–84) $37 295 n.a. $1068 $38 363
Outpatients d
 Medicaid outpatient cases 2 n.a. — e — e — e — e
 Medicare Supplemental outpatient cases 24 n.a. $95 $434 $58 $587
 Commercial outpatient cases 73 n.a. $451 n.a. $110 $561
Otitis externa
Inpatients
 Medicaid hospitalized cases 84 (4·8) 3·1 (1–40) $4741 n.a. $0 $4741
 Medicare Supplemental hospitalized cases 49 (2·0) 6·8 (1–125) $5966 $1702 $235 $7903
 Commercial hospitalized cases 387 (4·1) 2·5 (1–10) $5167 n.a. $743 $5910
Outpatients d
 Medicaid outpatient cases 63 863 n.a. $145 n.a. $0 $145
































 Medicare Supplemental outpatient cases 21 612 n.a. $55 $151 $53 $259
 Commercial outpatient cases 248 726 n.a. $136 n.a. $62 $198
NTM infection
Inpatients
 Medicaid hospitalized cases 29 (31·0) 12·1 (1–83) $21 041 n.a. $0 $21 041
 Medicare Supplemental hospitalized cases 226 (4·0) 10·4 (1–204) $16 960 $3487 $340 $20 787
 Commercial hospitalized cases 426 (29·6) 10·5 (1–108) $37 197 n.a. $1235 $38 432
Outpatients d
 Medicaid outpatient cases 81 n.a. $1073 n.a. $0 $1073
 Medicare Supplemental outpatient cases 1292 n.a. $275 $680 $114 $1069
 Commercial outpatient cases 1521 n.a. $1335 n.a. $183 $1518
Pulmonary NTM infection
Inpatients
 Medicaid hospitalized cases 5 (40·0) 13·2 (2–22) $12 725 n.a. $0 $12 725
 Medicare Supplemental hospitalized cases 152 (2·0) 10·7 (1–204) $20 472 $2606 $324 $23 402
 Commercial hospitalized cases 209 (23·0) 10·4 (1–108) $36 570 n.a. $1009 $37 579
Outpatients d
 Medicaid outpatient cases 27 n.a. $311 n.a. $0 $311
 Medicare Supplemental outpatient cases 754 n.a. $286 $729 $120 $1136
 Commercial outpatient cases 674 n.a. $1415 n.a. $199 $1649
Disseminated NTM infection
Inpatients
 Medicaid hospitalized cases 3 — e — e — e — e — e
 Medicare Supplemental hospitalized cases 45 (0·0) 9 (1–73) $9564 $2331 $415 $12 310
 Commercial hospitalized cases 120 (55·8) 12·1 (1–56) $46 081 n.a. $1042 $47 123
Outpatients d
 Medicaid outpatient cases 6 n.a. $1295 n.a. $0 $1295
 Medicare Supplemental outpatient cases 180 n.a. $271 $592 $97 $960




 Medicaid hospitalized cases 35 (5·7) 3·0 (1–26) $4328 n.a. $0 $4328
 Medicare Supplemental hospitalized cases 65 (4·6) 4·3 (1–19) $6037 $1570 $354 $7961
 Commercial hospitalized cases 246 (5·7) 3·8 (1–57) $9945 n.a. $861 $10 806
Outpatients d
 Medicaid outpatient cases 37 n.a. $288 n.a. $0 $288
 Medicare Supplemental outpatient cases 26 n.a. $121 $175 $43 $339
 Commercial outpatient cases 184 n.a. $606 n.a. $110 $716


































 Medicaid hospitalized cases 234 (0·4) 3·5 (1–27) $4036 n.a. $0 $4036
 Medicare Supplemental hospitalized cases 111 (3·6) 5·4 (1–25) $6706 $1610 $289 $8605
 Commercial hospitalized cases 661 (2·7) 3·9 (1–39) $7757 n.a. $930 $8687
Outpatients d
 Medicaid outpatient cases 132 n.a. $235 n.a. $0 $235
 Medicare Supplemental outpatient cases 50 n.a. $445 $351 $111 $907
 Commercial outpatient cases 382 n.a. $348 n.a. $69 $417
Shigellosis
Inpatients
 Medicaid hospitalized cases 80 (2·5) 3·0 (1–15) $3510 n.a. $0 $3510
 Medicare Supplemental hospitalized cases 18 (5·6) 11·6 (1–89) $11 857 $5727 $257 $17 841
 Commercial hospitalized cases 151 (4·0) 3·6 (1–19) $8720 n.a. $955 $9675
Outpatients d
 Medicaid outpatient cases 204 n.a. $134 n.a. $0 $134
 Medicare Supplemental outpatient cases 101 n.a. $56 $201 $61 $318
 Commercial outpatient cases 579 n.a. $221 n.a. $77 $298
Haemolytic uraemic syndrome
Inpatients
 Medicaid hospitalized cases 48 (27·1) 14·4 (1–150) $29 968 n.a. $0 $29 968
 Medicare Supplemental hospitalized cases 7 (28·6) 22·9 (9–69) $28 134 $13 640 $1029 $42 803
 Commercial hospitalized cases 177 (22·6) 11·1 (1–78) $62 158 n.a. $1447 $63 605
Outpatients d
 Medicaid outpatient cases 98 n.a. $585 n.a. $0 $585
 Medicare Supplemental outpatient cases 52 n.a. $215 $533 $93 $841
 Commercial outpatient cases 220 n.a. $2425 n.a. $166 $2591
Toxoplasmosis
Inpatients
 Medicaid hospitalized cases 10 (20·0) 10·1 (3–34) $19 647 n.a. $19 647 $39 294
 Medicare Supplemental hospitalized cases 7 (0·0) 8 (1–20) $21 177 $14 594 $211 $35 982
 Commercial hospitalized cases 76 (51·3) 10·5 (1–138) $53 634 n.a. $1149 $54 783
Outpatients d
 Medicaid outpatient cases 61 n.a. $1127 n.a. $0 $1127
 Medicare Supplemental outpatient cases 86 n.a. $96 $253 $63 $412
 Commercial outpatient cases 541 n.a. $536 n.a. $114 $650
NTM, Non-tuberculous mycobacteria; n.a., not applicable.
Data sources: Marketscan 2004–2005 Multistate Medicaid and 2006–2007 Medicare Supplemental and Commercial Claims databases. All costs in 
2007 US dollars.
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a
Insurer cost : total amount paid by the insurer to the healthcare provider.
b
Supplemental cost : for Medicare enrollees, this amount includes payments from the employer-provided supplemental plan. All patients in the 
Marketscan Medicare Supplemental database are enrolled in an employer-provided supplemental plan. For persons without a supplemental plan, 
this would most likely represent an out-of-pocket cost.
c
Out-of-pocket cost : total amount paid by the insured person, including deductibles, co-payments, and co-insurance.
d
Outpatient visits associated with an inpatient admission within 7 days were excluded from the outpatient set and included with inpatient costs.
e
Costs were not reported for groups of <5 cases.
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Table 2
Estimates of the annual prevalence and total cost (in US$) of hospitalizations for selected waterborne diseases 
in the USA
Medicaid Medicare Commercial Uninsured Total
PRIMARILY WATERBORNE
Giardiasis
 Mean total cost/hospitalization $3863 $11 842 $10 588 — a $9607
 Proportion of hospitalizations with
  type of insurance
20% 29% 39% 9%
 Number of hospitalizations/year 716 1038 1397 306 3581
 Total hospitalization cost $2 766 681 $12 297 799 $14 787 095 — a $34 401 449b
Cryptosporidiosis
 Mean total cost/hospitalization $16 203 $9361 $20 073 $16 797
 Proportion of hospitalizations
  with type of insurance
21% 23% 47% 9%
 Number of hospitalizations/year 572 627 1281 233 2725
 Total hospitalization cost $9 272 167 $5 867 007 $25 708 495 — a $45 770 572b
Legionnaires’ disease
 Mean total cost/hospitalization — c $26 741 $38 363 — a $33 366
 Proportion of hospitalizations with
  type of insurance
8% 43% 39% 6%
 Number of hospitalizations/year 1040 5590 5070 795 13 000
 Total hospitalization cost — c $149 482 190 $194 500 410 — a $433 752 020b
Otitis externa
 Mean total cost/hospitalization $4741 $7903 $5910 — a $6293
 Proportion of hospitalizations with
  type of insurance
15% 28% 45% 7%
 Number of hospitalizations/year 664 1239 1992 316 4426
 Total hospitalization cost $3 147 550 $9 794 030 $11 770 947 — a $27 851 446
NTM infection
 Mean total cost/hospitalization $21 041 $20 787 $38 432 — a $25 985
 Proportion of hospitalizations with
  type of insurance
22% 48% 21% 5%
 Number of hospitalizations/year 3679 7933 3416 750 16 386
 Total hospitalization cost $77 402 622 $164 909 131 $131 270 710 — a $425 788 469b
Pulmonary NTM infection d
 Mean total cost/hospitalization $12 725 $23 402 $37 579 — a $25 409
 Proportion of hospitalizations 16% 57% 20% 4%
 Number of hospitalizations/year 1248 4386 1510 290 7659
 Total hospitalization cost $15 885 069 $102 632 748 $56 753 918 — a $194 597 422b
Disseminated NTM infection d
 Mean total cost/hospitalization $21 080 $12 310 $47 123 — a $23 388
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Medicaid Medicare Commercial Uninsured Total
 Proportion of hospitalizations with
  type of insurance
31% 40% 19% 6%
 Number of hospitalizations/year 2008 2573 1221 360 6447
 Total hospitalization cost $42 337 221 $31 675 113 $57 535 633 — a $161 895 431b
Primarily waterborne total hospitalizations/year 6671 16 428 13 155 2400 40 118
Primarily waterborne total cost d $92 589 019e $342 350 156 $378 037 657 — a $967 563 956b
PARTIALLY WATERBORNE
Campylobacteriosis
 Mean total cost/hospitalization $4328 $7961 $10 806 — a $8915
 Proportion of hospitalizations with
  type of insurance
16% 30% 45% 6%
 Number of hospitalizations/year 2118 3972 5958 753 13 240
 Total hospitalization cost $9 168 435 $31 621 092 $64 382 148 — a $118 048 105b
Salmonellosis
 Mean total cost/hospitalization $4036 $8605 $8687 — a $7687
 Proportion of hospitalizations with
  type of insurance
21% 28% 41% 6%
 Number of hospitalizations/year 4857 6476 9482 1426 23 128
 Total hospitalization cost $19 602 368 $55 724 603 $82 374 304 — a $177 792 568b
Shigellosis
 Mean total cost/hospitalization $3510 $17 841 $9675 — a $8721
 Proportion of hospitalizations with
  type of insurance
38% 17% 32% 10%
 Number of hospitalizations/year 2087 933 1757 542 5491
 Total hospitalization cost $7 323 896 $16 654 038 $17 000 136 — a $47 884 375b
Haemolytic uraemic syndrome
 Mean total cost/hospitalization $29 968 $42 803 $63 605 — a $51 261
 Proportion of hospitalizations with
  type of insurance
20% 27% 46% 4%
 Number of hospitalizations/year 475 641 1092 99 2373
 Total hospitalization cost $14 222 813 $27 424 310 $69 429 946 — a $121 642 495b
Toxoplasmosis
 Mean total cost/hospitalization $39 294 $35 982 $54 783 — a $44 705
 Proportion of hospitalizations with
  type of insurance
42% 19% 17% 14%
 Number of hospitalizations/year 3733 1689 1511 1286 8889
 Total hospitalization cost $146 699 434 $60 770 360 $82 784 235 — a $397 386 567b
Partially waterborne total hospitalizations/year 13 270 13 711 19 800 4106 53 121
Partially waterborne total cost $197 016 945 $192 194 403 $315 970 768 — a $862 754 111b
NTM, Non-tuberculous mycobacteria.
Data sources : 2006–2007 Nationwide Inpatient Sample; Marketscan 2004–2005 Multistate Medicaid and 2006–2007 Medicare Supplemental and 
Commercial Claims databases. All costs in 2007 US dollars.
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a
Costs for uninsured patients could not be estimated from the insurance claims-based Marketscan databases.
b
Totals are higher than the sum of Medicaid, Medicare, and Commercial columns because the total includes the uninsured and other insurance 
sources (e.g. Tricare).
c
The number of cases of Legionnaires’ disease in the Marketscan Medicaid database was too small (<5 cases) to calculate cost estimates.
d
Pulmonary and disseminated NTM infections were a subset of all NTM infections and are not included in total cost calculations.
e
Not including Legionnaires’ disease costs.
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